Previous 10 | Next 10 |
Aurora Cannabis (NYSE: ACB ) initiated with Buy rating and C$16.50 (35% upside) price target at Desjardins. Shares up 1% premarket on the heels of its license deal with EnWave. More news on: Aurora Cannabis Inc., Gilead Sciences, Inc., Tocagen Inc., Healthcare stocks news, Stoc...
TEMPLE CITY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2019 financial results after the market closes on Tuesday May 7, 2019. The c...
Fulgent Genetics ( FLGT ) is a genetic testing contractor with proprietary technology enabling a host of different genetic tests. The share price has been on a roll lately, but we think after some consolidation, this could resume as the shares still aren't all that expensive. The evolution h...
Fulgent Genetics, Inc. (FLGT) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Nicole Borsje – Head of Investor Relations Ming Hsieh – Chief Executive Officer Paul Kim – Chief Financial Officer Conference Call Participants...
Fulgent Genetics (NASDAQ: FLGT ): Q4 Non-GAAP EPS of $0.01 beats by $0.02 ; GAAP EPS of -$0.05 misses by $0.02 . More news on: Fulgent Genetics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Fourth Quarter 2018 Results : Revenue totals $5.7 million, growing 33% year over year Billable tests delivered total 6,408, growing 52% year over year GAAP loss of $935,000, or $0.05 per share Non-GAAP loss of $193,000, or $0.01 per share Adjusted EBITDA of $50,000 Full Year 20...
TEMPLE CITY, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday Feb...
Fulgent Genetics (NASDAQ: FLGT ): Q3 Non-GAAP EPS of $0.00 beats by $0.04 ; GAAP EPS of -$0.03 beats by $0.01 . More news on: Fulgent Genetics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Third Quarter 2018 Results : Revenue totals $5.6 million, growing 25% year over year and 4% sequentially Billable tests delivered total 5,569, growing 37% year over year GAAP gross margin improves 70 basis points sequentially Non-GAAP gross margin remains flat sequentially GAAP los...
TEMPLE CITY, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2018 financial results after the market closes on Tuesday November 6, 2018. T...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a...